Evidence‐based clinical practice guidelines for renal cell carcinoma (Summary – JUA 2007 Edition)

Fujioka, Tomoaki; Obara, Wataru

doi:10.1111/j.1442-2042.2008.02242.x

Cited by 11 publications

(8 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous reports have stated that in addition to the radicality of the operation, the DFI, size/number of metastases, and operation time were correlated significantly with OS [10,17,18]. Hofmann et al [10] reported that a group with a DFI \36 months and multiple metastases, regardless of complete resection, had a 21.5% 5-year survival rate (MS 35 months) and did worse than other groups undergoing complete resection.…”

Section: Discussionmentioning

confidence: 95%

“…Many reports have suggested that the role of pulmonary metastasectomy is important in a limited number of patients who are completely resected or who have a limited number of metastases [9][10][11]. A metastasectomy is recommended by the current Japanese Urological Association Guidelines only when the patient has good performance status and the metastasis can be resected completely [17]. Until now, although several Japanese studies have reported on pulmonary metastasectomy in patients with RCC, the reported selection criteria for metastasectomy in patients with RCC has varied among the studies and has not been evaluated in a randomized, prospective trial.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Pulmonary metastasectomy in patients with renal cell carcinoma: a single-institution experience

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 98%

Pulmonary metastasectomy in patients with renal cell carcinoma: a single-institution experience

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Since the approval for use on RCC by the Ministry of Health in 1987, IFN‐α, in particular the natural type, has been widely used in Japan, and IFN‐α monotherapy for advanced RCC was recommended as grade A in the clinical practice guidelines for the management of RCC, compiled by JUA (2007 edition) 8 . However, the response rate and survival benefit achieved by this cytokine are only 6–15% and 3–5 months respectively, which are not satisfactory levels 9 …”

Section: Immunotherapymentioning

confidence: 99%

Current status of pharmacotherapy against metastatic renal cell carcinoma in Japan

et al. 2012

View full text Add to dashboard Cite

So far, metastatic renal cell carcinoma has been one of the most treatment‐resistant cancers. The extensive use of cytokines, such as interferon‐α and interleukin‐2, were carried out for metastatic renal cell carcinoma. However, significant advances in understanding the molecular mechanisms underlying renal cell carcinoma have led to the development of molecular target‐based drugs, which were desperately awaited for a long time, and now two types of molecular target‐based drugs are available. Two vascular endothelial growth factor receptor tyrosine kinase inhibitors and two mammalian target of rapamycin inhibitors have been approved and available in Japan. The molecular target‐based drugs have unique and characteristic adverse events, whose profile are not well understood in Japanese patients, because most of the clinical trials were carried out in Europe and America. In contrast, immunotherapy is being reconsidered in the selection of more appropriate patients or as a combined treatment form with other drugs, because of few complete responses obtained and unexpected adverse events by molecular targeted treatments. We have several molecular targeted‐drugs available at present and will have more, and we will actually use these drugs in various clinical settings, such as the presurgical setting, the adjuvant setting, sequential administration and combined administration, in addition to cytokines. Therefore, we need more elaborate studies to obtain the optimal treatment methods to maximize the effect of such agents to extend overall survival while maintaining quality of life of metastatic renal cell carcinoma patients. In this article, we reviewed the issues related to the current status of pharmacotherapy available for metastatic renal cell carcinoma.

show abstract

“…Renal function-preserving surgery has recently been recommended as a treatment for small renal cancer [1–3]. Percutaneous cryoablation therapy, which includes thermal ablation, for humans was initially reported by Uchida [4].…”

Section: Introductionmentioning

confidence: 99%

Preoperative lipiodol marking and its role on survival and complication rates of CT-guided cryoablation for small renal masses

Hongo¹,

Yamada²,

Ueda³

et al. 2017

BMC Urol

View full text Add to dashboard Cite

BackgroundPartial nephrectomy for small renal masses (SRM) may be useful for preserving renal function, but is technically more difficult than radical nephrectomy. Cryoablation may be performed under local anesthesia. The objective of the present study is to assess the safety and therapeutic efficacy of cryoablation with lipiodol marking for SRM.MethodsCryoablation therapy was performed on 42 patients under local anesthesia. Their median age was 74 years (31–91). The median tumor diameter was 21 mm (10–42). Responses to the treatment were evaluated using modified Response Evaluation Criteria in Solid Tumors (mRECIST) by contrast-enhanced CT. In six patients (14.3%) for whom it was not possible to use contrast medium, plain CT findings were assessed according to Response Evaluation Criteria in Solid Tumors (RECIST).ResultsTwenty-nine (69%) and five (12%) patients achieved complete responses (CR) and partial responses (PR), respectively, while four (10%) and four (10%) patients each had stable disease (SD) and progressive disease (PD) after the first course of therapy. A second course of cryoablation therapy with lipiodol marking was performed on three out of four patients with PD after the first course of therapy, and resulted in a total of 32 patients achieving CR (76%). Four (36.4%) out of 11 patients for whom lipiodol marking was not conducted had PD, whereas none of the 31 patients for whom lipiodol marking was conducted had PD. All grade complications were reported in 11 (24.4%) patients while grade 3 in two (4.4%) patients. 11 (24.4%) A significant difference was observed in postoperative hemorrhagic events in all grades (18% in patients undergoing cryoablation without lipiodol marking vs. 0% in patients undergoing cryoablation without lipiodol marking).ConclusionsAlthough further studies involving more patients are needed in order to evaluate long-term results, cryoablation therapy appears to be a useful treatment option for SRM. Preoperative marking with lipiodol was helpful for improving complication and survival rates with cryoablation.

show abstract

Evidence‐based clinical practice guidelines for renal cell carcinoma (Summary – JUA 2007 Edition)

Cited by 11 publications

References 106 publications

Pulmonary metastasectomy in patients with renal cell carcinoma: a single-institution experience

Pulmonary metastasectomy in patients with renal cell carcinoma: a single-institution experience

Current status of pharmacotherapy against metastatic renal cell carcinoma in Japan

Preoperative lipiodol marking and its role on survival and complication rates of CT-guided cryoablation for small renal masses

Contact Info

Product

Resources

About